drugset / Trial / NCT07379580
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
Phase 2
Recruiting
310 enrolled
BioNTech SE
Coalition for Epidemic Preparedness Innovations · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
Timeline
- Start
- 2026-02-20
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BNT166a | Messenger RNA (mRNA) | — | Intramuscular |